Antiverse Series A

Antiverse, an AI-driven drug discovery company, has raised $9.3 million in a Series A funding round. The company utilizes artificial intelligence to accelerate the discovery and development of novel antibodies. This funding will support Antiverse's continued expansion of its AI platform and pipeline.